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ASSESSING INTERFERON-ALPHA MONOTHERAPY IN PATIENTS WITH 
ADVANCE OR METASTATIC RENAL CELL CARCINOMA
Rai MK1, Nair SR1, McEwan P2
1CRC, Capita India Pvt. Ltd, Mumbai, Maharashtra, India; 2CRC, Cardiff, UK
OBJECTIVES: The objective was to evaluate the clinical efﬁ cacy and safety of inter-
feron-α 2a (IFN) in the treatment of advanced/metastatic renal cell carcinoma in 
treatment-naïve patients. METHODS: Studies were retrieved from Embase, Pubmed, 
Cochrane, and DARE databases using relevant search strategies. Randomized con-
trolled trials, which compared IFN with other pharmacological interventions/best 
supportive care (BSC), were included according to prespeciﬁ ed inclusion/exclusion 
criteria. The outcomes of interest were overall survival (OS), progression free survival 
(PFS), response rate (RR), and adverse events (AEs). Two reviewers independently 
extracted data from the included studies. Data were analyzed using RevMan (5). 
RESULTS: Of the 736 studies identiﬁ ed, seven studies met the inclusion criteria. In 
total, 1147 patients were randomized to IFN, and 1150 were randomized to compara-
tor interventions. Two studies reported comparison with interleukin-2 (IL-2), two with 
BSC and one each with sorafenib, sunitinib, and temsirolimus. Median OS ranged 
from 9 to 21.8 months with IFN. Progression-free survival ranged from 1.9 to 5.6 
months and overall RR ranged from 4.83% to 12.27% with IFN. Sunitinib had sig-
niﬁ cantly better overall RR (P < 0.001), PFS (P < 0.001), and OS (P < 0.01) compared 
to IFN. Sorafenib and temsirolimus had better overall RR than IFN (P < 0.01). Results 
of meta- analysis demonstrate that IFN has better overall RR than BSC (OR: 2.51 
[95% CI: 0.87, 7.27], P = 0.089) and similar RR as IL-2 (OR: 1.09 [95% CI: 0.48, 
2.45], P = 0.836). The AE proﬁ le (gastrointestinal, vascular, infectious, and blood 
disorders) was similar with IFN and comparators. CONCLUSIONS: Survival beneﬁ t 
with IFN-α was lower than the newer therapeutic agents. Anti-angiogenic agents 
targeting through multiple receptor kinases, such as sunitinib and sorafenib have 
signiﬁ cantly improved response rates and survival. These agents would be preferred 
for treatment naïve patients with advanced/metastatic renal cancer.
PCN8
CLINICAL AND ECONOMIC BURDEN OF TOXICITIES ASSOCIATED 
WITH MONOCLONAL ANTIBODIES FOR METASTATIC COLORECTAL 
CANCER (MCRC)
Burudpakdee C1, Zhao Z2, Trochlil K1, Gao SK3, Munakata J4, Barber B3
1IMS Consulting, Falls Church, VA, USA; 2Amgen, Newbury Park, CA, USA; 3Amgen Inc., 
Thousand Oaks, CA, USA; 4IMS Health, Redwood City, CA, USA
OBJECTIVES: As overall survival improves with newer therapies for mCRC, treatment-
limiting toxicities and related costs will be important when evaluating treatment deci-
sions. Little is known about toxicity-related cost of currently available monoclonal 
antibody treatments. This study was designed to identify cetuximab-, bevacizumab-, and 
panitumumab-related toxicities and estimate direct costs of treating these toxicities. 
METHODS: A comprehensive literature search was performed to identify English 
language phase II/III studies of monoclonal antibodies for mCRC. The search utilized 
PubMed, conference abstracts, treatment guidelines, and product labels. Commonly 
reported grade 3 and 4 toxicities were identiﬁ ed, and outpatient and inpatient costs 
were estimated for all toxicities. Outpatient costs were estimated by applying 2010 
Medicare reimbursement rates to resource use assumptions (assessed based on in-
depth clinical interviews). Inpatient costs were estimated using ICD-9 codes and 2007 
Medicare payments from the HCUP database; then were converted to 2010 values 
using the Consumer Price Index for medical care services. RESULTS: Clinically sig-
niﬁ cant toxicities associated with bevacizumab include hypertension, arterial throm-
bosis, hemorrhage, gastrointestinal (GI) perforation, ﬁ stula, and wound healing 
complication; while treatment-related toxicities associated with cetuximab and pani-
tumumab include skin rash, hypomagnesemia, and infusion reactions, although the 
incidence of these toxicities differ between the two drugs. Cost of toxicities treated in 
outpatient setting ranged from $185 (hypertension and skin rash) to $585 (wound-
healing complications). Inpatient cost per event for GI perforation is the highest at 
$32,443, followed by ﬁ stula $29,062, arterial thrombosis $20,346, wound healing 
complication $13,240, hemorrhage $12,956, infusion reaction $10,326, and hyperten-
sion $8453, while inpatient cost per event for skin rash and hypomagnesemia is among 
the lowest at $4424 and $6174, respectively. CONCLUSIONS: Monoclonal antibod-
ies have different toxicity proﬁ les and the costs associated with managing these toxici-
ties vary greatly.
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OBSERVATIONAL STUDY OF PATIENTS WITH NON SMALL CELL 
LUNG CANCER (NSCLC) TREATED BY ERLOTINIB: CLINICAL 
PRACTICES AND MAIN OUTCOMES IN FRANCE
Vergnenegre A1, Monnet I2, Chouaid C3, Hureaux J4, Mazières J5, Quéré G6, 
Lombard JN7, Cumin I8, Abdiche S9, Nocent Ejnaini C10, Decroisette C11
1Hôpital du Cluzeau, Limoges, France; 2CHI Créteil, Créteil, France; 3Hôpital St Antoine, 
Paris, France; 4CHU Angers, Angers, France; 5CHU Toulouse, Toulouse, France; 6CHU 
Morvan, Brest, France; 7Cabinet de Pneumologie, Dijon, France; 8CH Bretagne Sud Site 
Lorient, Lorient, France; 9Hôpital Robert Boulin, Libourne, France; 10CHI Côte Basque, 
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OBJECTIVES: Few data are available about the use of erlotinib in real-life in France 
for patients with non small cell lung cancer (NSCLC) in a selected population. 
METHODS: An epidemiological multicenter observational study was built in 35 
french centers. The study was retrospective (2006 to 2008) and a cohort was created 
with a follow-up period of 1 year. The main objective was to describe practices, use 
of erlotinib, response, and adverse events. RESULTS: A total of 533 patients (333 
males, 200 females) have been included. The histological types were as follows: 330 
(62.5%) adenocarcinoma, 107 (20.2%) squamous cell carcinoma, 60 (11.3%) large 
cell carcinoma, 36 (3.8%) undifferentiated carcinoma. In terms of practice, 502 
patients had a ﬁ rst line chemotherapy (81% a doublet, 11% three drugs, 8.2% one 
drug). Among them, 61.2% received a second line of treatment (83.4% one drug, 
15.7% two drugs and 0.9% three drugs), 17.6% received a third line (91% one drug). 
Erlotinib was prescribed a ﬁ rst line treatment (n = 30; 5.6%), second line treatment 
(n = 190; 35.6%), third line (255; 47.8%), fourth line, and more (n = 50; 9.3%) and 
as a maintenance therapy (n = 9; 1.7%); the stage at treatment initiation were stage 
I–II (1.2%), IIIA (3.8%), IIIB (5.3%), and IV (89.7%). For the ﬁ rst line, the median 
duration of erlotinib treatment was 123 days (d) in second line 98 d, in third line 
77 d, in maintenance 127 d. Global response rate was 20% with a maximum of 32% 
in ﬁ rst line and 33% in maintenance. Grade III adverse events occurred in 11.5% of 
patients and grade IV in 3.4%. CONCLUSIONS: Erlotinib was widely used in France 
in 2d and 3d line treatment with a good response rate and tolerance. Adenocarcinoma 
is the main indication.
PCN10
EXPLORATIVE ANALYSIS ABOUT THE POTENTIAL OF A LARGE GPS 
LONGITUDINAL DATABASE ON SEARCHING CAUSAL ASSOCIATIONS 
AMONG PATHOLOGIES
Katz PM, Heiman F
BKL Consulting SRL, Milan, Italy
OBJECTIVES: The main objective of this study was to analyze different approaches 
and methods to explore potential causal associations among prevalent pathologies. 
We have focused on diabetes mellitus (DM) and its well-known association with 
incident neoplasia. METHODS: For this retrospective cohort study, data were 
obtained from CSD LPD, a General Practitioner’s longitudinal database. We have 
evaluated the risk of neoplasia incidence among people with diabetes mellitus com-
pared with those without this pathology, in patients who had no reported history of 
benign or malign neoplasia at the start of the follow-up on January 2006. For the DM 
group, patients with at least one diagnosis of DM from January 2005 to December 
2005 have been selected, while for the DM-free group, patients without a diagnosis 
of DM and a date of registration in the GPs ofﬁ ce before January 2006 have been 
selected. Both groups have been followed up for 48 months. RESULTS: During the 
selection period, 45.121 (3.4%) patients with a diagnosis of DM (females: 22.330, 
males: 22.791) and 1.290.597 (96, 6%) patients without a diagnosis of DM (females: 
690.462, males: 600.135) have been selected. During the follow-up 6.648 and 80.880 
incident cases of neoplasms have been documented from the DM and DM free groups 
respectively. The mean follow-up duration was 43 and 45 months for the DM and 
the DM-free groups respectively. CONCLUSIONS: The selected cohort has shown to 
match quite well with general population in terms of gender and age. The estimated 
prevalence of diabetes also matches with the one of the general population. Statistical 
analysis has shown an adjusted (for age and sex) hazard ratio of 1,88 (95% Cl 
1,83–1,93) suggesting an association between DM and incident neoplasms, evidencing 
that GPs longitudinal databases could be a valid instrument for evaluating causal 
association among prevalent pathologies.
PCN11
GEFITINIB COMPARED WITH DOUBLET CHEMOTHERAPY FOR 
FIRST-LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER 
(NSCLC): A SYSTEMATIC REVIEW AND ADJUSTED INDIRECT 
COMPARISON
Edwards SJ1, Welton N2, Borrill J1
1AstraZeneca UK Ltd, Luton, Bedfordshire, UK; 2University of Bristol, Bristol, UK
OBJECTIVES: Objective response rate (ORR) is an early indicator of successful treat-
ment in patients with NSCLC. This research compared geﬁ tinib with platinum-based 
doublet chemotherapies for ﬁ rst-line treatment of advanced NSCLC in patients harbor-
ing activating epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutations 
(M+). METHODS: Systematic searching of CENTRAL, EMBASE, and MEDLINE for 
randomized controlled trials (RCTs) comparing ≥2 doublet chemotherapies (carbopla-
tin or cisplatin in combination with either docetaxel, gemcitabine, paclitaxel, peme-
trexed, or vinorelbine) for the ﬁ rst-line treatment of advanced NSCLC was completed 
in May 2009. a meta-analysis was performed on ORR using data from published 
RCTs of geﬁ tinib versus paclitaxel/carboplatin in EGFR-TK M+ patients. a mixed 
treatment comparison (MTC) was carried out with doublet chemotherapies in 
unselected advanced NSCLC patients using paclitaxel/carboplatin as a baseline. Treat-
ment effect was calculated as an odds ratio (OR) with 95% credible interval (95% 
CrI). a sensitivity analysis was conducted on the inclusion of the geﬁ tinib trials within 
the MTC. For this analysis, it was assumed that the efﬁ cacy of doublet chemotherapy 
is consistently affected by EGFR-TK mutation status. RESULTS: Three RCTs were 
identiﬁ ed for geﬁ tinib, of which two were comparisons with paclitaxel/carboplatin. 
Meta-analysis of these two trials gave an estimated ORR favoring geﬁ tinib: OR 4.04, 
95% conﬁ dence interval: 2.73–5.98. Twenty-nine trials were appropriate for inclusion 
in the MTC, of which 25 reported ORR. The MTC found no signiﬁ cant difference in 
ORR among other doublet chemotherapies versus paclitaxel/carboplatin, with the 
exception of pemetrexed/cisplatin, in patients with predominantly non-squamous 
tumor cell histology, which was associated with a signiﬁ cantly higher ORR (OR 1.64, 
95% CrI: 1.15–2.27). In the sensitivity analysis, ORR was signiﬁ cantly higher with 
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geﬁ tinib versus all doublet chemotherapies (geﬁ tinib vs. pemetrexed/cisplatin OR 3.05, 
95% CrI: 1.58–5.51). CONCLUSIONS: This adjusted indirect comparison suggests 
that geﬁ tinib may have important ORR advantages over other ﬁ rst-line treatments in 
EGFR-TK M+ patients.
PCN12
EFFICACY OF SECOND LINE TREATMENTS IN PATIENTS WITH 
METASTATIC HORMONE REFRACTORY PROSTATE CANCER (MHRPC) 
IS NOT DEMONSTRATED BY PUBLISHED EVIDENCE FROM NON-
RANDOMIZED TRIALS
Freemantle N1, Mason M2, Jasso Mosqueda JG3, Nixon F4, Budhia S4
1University of Birmingham, Birmingham, UK; 2Cardiff Medical School, Cardiff, UK; 
3Sanoﬁ -Aventis, Massy, France; 4Heron Evidence Development Ltd, Luton, UK
OBJECTIVES: Standard ﬁ rst-line treatment for patients with mHRPC is Docetaxel(D)-
based chemotherapy. Published results from randomized clinical trials of second-line 
treatments after D failed to provide deﬁ nitive conclusions about clinical efﬁ cacy largely 
due to paucity of data. This study sought to identify nonrandomized trials of second-
line chemotherapy in mHRPC patients pretreated with D and present related survival 
and clinical beneﬁ ts. METHODS: Pubmed and Embase were used to perform a sys-
tematic literature review (SLR) (2000–2010). Both comparative and noncomparative 
nonrandomized evidence were extracted from prospective and retrospective studies. 
Targeted population was patients with mHRPC failing previous D-based regimens. 
End points included overall-survival (OS), progression-free-survival (PFS), and PSA-
response rate. RESULTS: Among the 825 records screened, 30 studies met the inclu-
sion criteria, two of which were comparative. Of these, 10 addressed rechallenge with 
D and seven addressed mitoxantrone (MTX); the remaining 18 studies considered 
various other regimens. Treatment was with either single-agent or combination regi-
mens. Ninety-three percent of studies included <50 patients. PFS and PSA response 
deﬁ nitions varied between trials. For studies evaluating rechallenge with D, the median 
OS and PFS varied from 41 to 76 weeks and from 15 to 39 weeks respectively. For 
MTX, the median OS and PFS varied from 39 to 48 weeks and 13 to 16 weeks, 
respectively. For other chemotherapy regimens, the median OS and PFS varied from 
51 to 104 weeks and 9 to 17 weeks, respectively. PSA response rates varied from 24% 
to 70% to D rechallenge, from 4% to 33% to MTX-based regimens and from 0% to 
60% to other regimens. CONCLUSIONS: The SLR showed a lack of available non-
randomized evidence, and among the selected studies, evidence was not strong enough 
due to small sample sizes, noncomparative nature and variable PFS and PSA response 
deﬁ nitions. This literature review demonstrates that it is difﬁ cult to infer the clinical 
efﬁ cacy of mHRPC 2nd line chemotherapy.
PCN13
EFFECT OF ZOLEDRONIC ACID AND PAMIDRONATE ON SKELETAL-
RELATED EVENTS AND MORTALITY IN WOMEN WITH BONE 
METASTASES FROM BREAST CANCER IN A MANAGED CARE PLAN: A 
RETROSPECTIVE DATABASE ANALYSIS
Henk HJ1, Kaura S2
1i3 Innovus, Eden Prairie, MN, USA; 2Novartis Pharmaceuticals Corporation, Florham Park, 
NJ, USA
OBJECTIVES: Patients with breast cancer (BC) and bone metastases are at risk for 
skeletal-related events (SREs) that are associated with signiﬁ cant morbidity, mortality, 
and reduced quality of life. The intravenous bisphosphonates (IVBPs) zoledronic acid 
(ZOL) and pamidronate (PAM) are approved for treating patients with bone metas-
tases from BC. We compared incidence of SREs and mortality in women with BC who 
received ZOL or PAM, and assessed the long-term beneﬁ t of ZOL in a real-world 
setting. METHODS: A claims-based analysis of commercial and Medicare Advantage 
data from >45 US managed care plans was used to evaluate SRE rates and mortality 
in patients treated with ZOL or PAM. Inclusion criteria were age >18 years, BC with 
bone metastasis diagnosis between 01/01/01 and 12/31/06, continuous enrollment in 
the health plan, no evidence of bone metastasis or IVBP for 6 months before an index 
date of ﬁ rst receipt of ZOL or PAM. Patients were followed until disenrollment 
(including mortality) or study completion (12/31/07). Persistency was deﬁ ned as the 
absence of a >45-day gap between treatments. SREs were deﬁ ned as evidence of 
pathologic fracture, spinal cord compression, and radiotherapy or surgery to bone. 
RESULTS: Among 8757 patients (mean age, 58.1 ± 12.4 years) approximately 30% 
received ZOL, 15% received PAM, and 55% received no IVBP. Longer persistency 
with ZOL was associated with lower risk of fracture and of all SREs versus shorter 
persistency (trend test, P = 0.0026 and P = 0.0216, respectively). ZOL-treated patients 
had a moderately lower SRE incidence (36.2 vs. 40.0 per 100 person-years; P = 
0.0707) and signiﬁ cantly fewer deaths (6.2 vs. 8.9 per 100 person-years; P = 0.0130) 
versus PAM-treated patients. CONCLUSIONS: In a real-world assessment of women 
with bone metastases from BC, ZOL reduced SRE incidence and signiﬁ cantly 
improved survival versus PAM. Longer ZOL persistency was associated with lower 
SRE risk, reinforcing the importance of regular monthly ZOL dosing.
PCN14
CLINICAL CONSEQUENCES OF PRIMARY PROPHYLAXIS WITH 
PEGFILGRASTIM VERSUS FILGRASTIM FOR THE PREVENTION OF 
FEBRILE NEUTROPENIA IN NON-HODGKIN LYMPHOMA AND STAGE II 
BREAST CANCER PATIENTS IN GERMANY
Ozer-Deniz S1, Taylor DC1, Hill G1, Skornicki M1, Danel A2, Kunz E3
1i3 Innovus, Medford, MA, USA; 2Amgen Inc., Zug, Switzerland; 3Amgen (Europe) GmbH, 
München, Germany
OBJECTIVES: To assess the clinical consequences of primary prophylaxis (PP) with 
pegﬁ lgrastim versus 6- or 11-day ﬁ lgrastim (F6, F11) in the prevention of febrile 
neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients receiving CHOP-14 
chemotherapy and in breast cancer (BC) patients receiving TAC chemotherapy in 
Germany. METHODS: A lifetime Markov model was developed, consisting of two 
phases: 1) on-chemotherapy phase (OCP), where model cycle length equals chemo-
therapy cycle length (CHOP-14:14 days, TAC: 21 days), and 2) post-chemotherapy 
phase (PCP) with annual model cycles. PP is deﬁ ned as prophylaxis initiated with the 
ﬁ rst chemotherapy cycle. Cycle 1 FN risk with no prophylaxis (NP) was estimated to 
be 21% for NHL CHOP-14 and 14% for BC TAC. All cycle relative risk of FN using 
PP with pegﬁ lgrastim versus no PP, F6, and F11 was 0.25, 0.87, and 0.61. FN case 
fatality was estimated (NHL: 8.9%; BC: 3.6%). In PCP, all-cause mortality was 
estimated from German life-tables; NHL and BC mortality from US data; patients 
experiencing FN were assumed to have higher mortality due to reduced chemotherapy 
dose intensity. All inputs were estimated from clinical trials and published literature. 
The model estimates life-years, number of FNs, and number needed to treat (NNT) 
to prevent an FN. RESULTS: NNT to prevent an FN were 1.3, 6.2, 2.2 in NHL; 2.3, 
11.1, 4.0 in BC for Pegﬁ lgrastim, F6, and F11 compare to NP. Overall, FN episodes 
per patient were 0.15, 0.76, and 0.47 in NHL; 0.09, 0.43, and 0.27 in BC. Per-patient 
life-months gained using PP with Pegﬁ lgrastim were 3.4 and 1.8 versus F6 and F11, 
respectively in NHL, and 2.2 and 1.2 in BC. CONCLUSIONS: Primary prophylaxis 
with pegﬁ lgrastim results in a lower NNT, fewer FN events, and more life-years than 
with 6-day ﬁ lgrastim or 11-day ﬁ lgrastim in both NHL and BC.
PCN15
SYSTEMATIC REVIEW OF LAPATINIB PLUS LETROZOLE WITH OTHER 
FIRST LINE TREATMENTS FOR HORMONE POSITIVE (HR+) HER2+ 
ADVANCED OR METASTATIC BREAST CANCER (MBC)
Riemsma R1, Forbes CA1, Amonkar M2, Lykopoulos K3, Diaz JR4, Kleijnen J1, Rea DW5
1Kleijnen Systematic Reviews Ltd., York, North Yorkshire, UK; 2GlaxoSmithKline, Philadelphia, 
PA, USA; 3GlaxoSmithKline, London, UK; 4GlaxoSmithKline, Uxbridge, Middlesex, UK; 
5Institute for Cancer Studies, Birmingham, UK
OBJECTIVES: To undertake a systematic review of lapatinib plus letrozole (LAP + 
LET) with other ﬁ rst-line treatments for HR+ HER2+ advanced or MBC in postmeno-
pausal women who have not received prior therapy for advanced or metastatic disease. 
METHODS: Seven databases were searched through January 2009 for randomized 
controlled trials. Relevant interventions were lapatinib (alone/in combination), aro-
matase inhibitors (letrozole (LET), anastrozole (ANA), exemestane (EXE)), tamoxifen 
(TAM), and trastuzumab (TRAS) (alone/in combination). Outcomes included overall 
survival (OS), progression-free survival (PFS), time to progression (TTP), and objective 
response rate (ORR). From the available evidence, it was possible to directly compare 
LAP + LET with LET. Using a network meta-analysis, LAP + LET could be indirectly 
compared with the four other interventions. RESULTS: Eighteen studies (62 papers) 
met the inclusion criteria. LAP + LET was signiﬁ cantly superior to LET based on a 
direct head-to-head study in terms of PFS/TTP and ORR. In the indirect comparison 
with LAP + LET, TAM (hazard ratio [HR] = 0.45 [95% CI: 0.32, 0.65]), EXE (HR 
= 0.52 [0.34, 0.79]), and ANA (HR = 0.53 [0.36, 0.80]) scored signiﬁ cantly worse in 
terms of PFS/TTP and ORR (TAM: odds ratio [OR] = 0.25 [0.12, 0.53], ANA: OR 
= 0.27 [0.12, 0.58], EXE: OR = 0.47 [0.20, 1.09]). LAP + LET also seemed better, 
although not signiﬁ cantly, in terms of OS versus TAM: HR = 0.74 (0.49, 1.12), EXE: 
HR = 0.65 (0.39, 1.11), and ANA: HR = 0.71 (0.45, 1.14). LAP + LET when indirectly 
compared with TRAS + ANA, seemed to be better in terms of OS (HR = 0.85 [0.47, 
1.54]), PFS/TTP (HR = 0.89 [0.54, 1.47]) and ORR (OR = 0.92 [0.24, 3.48]), 
although, none of these results were signiﬁ cant. CONCLUSIONS: Using indirect 
methods, LAP + LET appeared to be the best treatment in this HR+ HER2+ patient 
population. However, the results are based on a network analysis for which the basic 
assumptions of homogeneity, similarity, and consistency were not fulﬁ lled. Therefore, 
despite the fact that these are the best available data, the results need to be interpreted 
with caution.
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MIXED TREATMENT COMPARISON OF BEVACIZUMAB-BASED 
THERAPIES RELATIVE TO DOUBLET-CHEMOTHERAPY COMBINATIONS 
TO ESTIMATE THE RELATIVE EFFICACY IN PROGRESSION-FREE 
SURVIVAL FOR TREATMENT OF FIRST-LINE ADVANCED OR 
METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Yi Y1, Chouaid C2, Vergnenegre A3, Bischoff HG4, Bergman G5, Walzer S6, Philips Z1
1Mapi Values, Bollington, UK; 2Hôpital Saint-Antoine, Paris, France; 3SIME, Limoges, France, 
4Thoraxklinik Heidelberg GmbH, Hedelberg, Germany; 5Mapi Values, Houten, The 
Netherlands; 6F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland
OBJECTIVES: To compare the efﬁ cacy in progression-free survival (PFS) of bevaci-
zumab plus cisplatin and gemcitabine (BCG) and bevacizumab plus carboplatin and 
paclitaxel (BCP), relative to doublet-chemotherapy combinations for the treatment of 
